XML 52 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
Liquidity and Capital Resources (Details) - USD ($)
9 Months Ended
Jun. 30, 2022
Jun. 16, 2022
Jun. 15, 2022
Jun. 02, 2022
May 30, 2022
Apr. 06, 2022
Sep. 30, 2022
Sep. 30, 2021
Apr. 08, 2022
Liquidity and Going Concern Considerations [Line Items]                  
Cash, cash equivalents and investments available-for-sale             $ 27,600,000    
Working capital             23,000,000    
Net cash used in operating activities             (16,820,000) $ (24,508,000)  
Minimum cash covenant             10,000,000    
Proceeds from sale of equity, net       $ 14,900,000          
Series X Convertible Preferred Stock                  
Liquidity and Going Concern Considerations [Line Items]                  
Consideration received           $ 15,000,000      
Proceeds from sale of equity, net           14,900,000      
Registered Direct Offering Warrants                  
Liquidity and Going Concern Considerations [Line Items]                  
Number of shares of common stock for which warrant is exercisable (in shares)         7,788,480        
Discount from stock price (dollars per share)         $ 0.0001        
Exercise price of warrant (in dollars per share)         $ 0.0001        
PIPE Purchase Agreement Pre-Funded Warrant                  
Liquidity and Going Concern Considerations [Line Items]                  
Number of shares of common stock for which warrant is exercisable (in shares)         1,267,897        
Discount from stock price (dollars per share)         $ 0.0001        
Exercise price of warrant (in dollars per share)         $ 0.0001        
PIPE Purchase Agreement Warrant                  
Liquidity and Going Concern Considerations [Line Items]                  
Number of shares of common stock for which warrant is exercisable (in shares)         9,900,990        
Exercise price of warrant (in dollars per share)         $ 1.39        
Warrant price (dollars per share)         $ 0.125        
Registered Direct Offering                  
Liquidity and Going Concern Considerations [Line Items]                  
Number of shares issued         844,613        
Common stock trading price (in dollars per share)         $ 1.39        
Registered Direct Offering | Registered Direct Offering Warrants                  
Liquidity and Going Concern Considerations [Line Items]                  
Discount from stock price (dollars per share)         0.0001        
Exercise price of warrant (in dollars per share)         $ 0.0001        
Da Vita Healthcare Partners Inc | Share Issuance, Tranche One                  
Liquidity and Going Concern Considerations [Line Items]                  
Proceeds from issuance of convertible preferred stock           7,500,000      
Da Vita Healthcare Partners Inc | Share Issuance, Tranche Two                  
Liquidity and Going Concern Considerations [Line Items]                  
Proceeds from issuance of convertible preferred stock   $ 7,500,000 $ 7,500,000            
Da Vita Healthcare Partners Inc | Private Placement | Series X Convertible Preferred Stock                  
Liquidity and Going Concern Considerations [Line Items]                  
Sale of stock, aggregate consideration authorized           $ 15,000,000      
Consideration received     $ 15,000,000            
Common stock trading price (in dollars per share)           $ 1,000      
Da Vita Healthcare Partners Inc | Private Placement | Share Issuance, Tranche One | Series X Convertible Preferred Stock                  
Liquidity and Going Concern Considerations [Line Items]                  
Number of shares issued           7,500      
Da Vita Healthcare Partners Inc | Private Placement | Share Issuance, Tranche Two | Series X Convertible Preferred Stock                  
Liquidity and Going Concern Considerations [Line Items]                  
Number of shares issued   7,500 7,500            
Cantor Fitzgerald & Co | Controlled Equity Offering                  
Liquidity and Going Concern Considerations [Line Items]                  
Sale of stock, aggregate consideration authorized             $ 12,200,000   $ 12,200,000
Number of shares issued 7,500                
Consideration received $ 15,135